Also, in patients with T2DM SGLT2 inhibitors and GLP1-RA (in the dose indicated for diabetes treatment) can reduce MACE, and in some cases, reduce overall mortality [3,5,6,28]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.